Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Boston Convention and Exhibition Center

Jun 23, 2013 8:30 AM - Jun 27, 2013 12:45 PM

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

The Importance of Country Selection in Clinical Study Design

Session Chair(s)

Joan  Meyer

Joan Meyer

Covance, United States

The importance of country selection as part of the overall clinical trial strategy will be discussed. The impact of country selection on patient recruitment and retention programs and how it impacts a company’s marketing plans will be considered.

Learning Objective : Discuss the importance of country selection in clinical study strategy and design; Describe the impact of country selection on patient recruitment and retention plans; Recognize the importance of proactively leveraging country selection to support marketing plan objectives.

Speaker(s)

Jeffrey S. Handen, PhD

Country-specific Differences in Data Quality and Clinical Grants Costs

Jeffrey S. Handen, PhD

Medidata Solutions Worldwide, United States

Vice President, Clinical Solutions

Lani  Hashimoto

Panelist

Lani Hashimoto

Novartis Pharmaceuticals Corporation, United States

Associate Director, Patient Engagement

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.